Frequently Asked Questions

Research peptides are short chains of amino acids (typically 2–50 amino acids) that are studied for their potential biological effects. They are distinct from proteins (which are longer chains) and are of significant interest in medical and pharmaceutical research due to their highly specific mechanisms of action.

The peptides listed on Peptides Hive are classified as research compounds — they are not FDA-approved for human therapeutic use (with some exceptions like semaglutide and tesamorelin) and are studied primarily in academic and pre-clinical research contexts.

The legal status of research peptides varies significantly by country and specific compound. In general:

• US: Most research peptides are not FDA-approved and are subject to pharmaceutical regulations. The FDA significantly restricted compounding of many peptides in 2024.
• Australia: Most are Schedule 4 (prescription required), with compounding access available in some cases.
• EU: Varies by member state — some countries have permissive research compound frameworks.

Always consult our Regulatory Guidance and verify current laws in your jurisdiction with a qualified legal or healthcare professional.

GHRH analogues (like CJC-1295 and sermorelin) are synthetic versions of Growth Hormone Releasing Hormone. They bind to GHRH receptors in the pituitary and stimulate GH synthesis and release by amplifying the natural GHRH signal. They produce a sustained increase in GH levels.

GHRPs (Growth Hormone Releasing Peptides — like Ipamorelin, GHRP-2, GHRP-6) work through a different receptor (ghrelin receptor / GHSR-1a) and produce a more pulsatile, acute GH release. They are often stacked with GHRH analogues for synergistic effects, as the two mechanisms amplify each other.

BPC-157 (Body Protection Compound-157) is a gastric pentadecapeptide that primarily acts locally at the site of injury. It is particularly effective for musculoskeletal, tendon, ligament, and gastrointestinal healing through nitric oxide pathway upregulation and angiogenesis promotion.

TB-500 (Thymosin Beta-4) works more systemically. It upregulates actin and promotes systemic tissue repair, wound healing, and anti-inflammatory effects throughout the body, not just at the local injection site.

The two are frequently combined because they offer complementary mechanisms — local (BPC-157) plus systemic (TB-500) repair support.

Most research peptides are supplied in lyophilised (freeze-dried) powder form. This process removes moisture to increase stability and shelf life. Before use, the powder must be reconstituted — dissolved in a liquid (usually bacteriostatic water) to create an injectable solution.

The lyophilisation process preserves the peptide's biological activity for much longer than a liquid solution can.

Bacteriostatic Water (BW) is the recommended reconstitution vehicle for most research peptides. It contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth and extends the useful life of the reconstituted solution to 4–6 weeks when refrigerated.

Sterile Water for Injection can also be used but does not contain a preservative, meaning the reconstituted solution must be used within 24–48 hours.

Normal saline (0.9% NaCl) is generally not recommended for peptide reconstitution as it can cause aggregation in some peptides.

Use our Reconstitution Calculator for precise calculations. The general formula is:

Volume of BW to add = (Desired concentration in mcg/mL) ÷ (Vial peptide content in mcg)

Example: 5mg (5,000 mcg) vial + 2mL BW = 2,500 mcg/mL concentration. A 100mcg dose would require 0.04mL (4 units on a U100 insulin syringe).

No. Once a peptide has been reconstituted into solution, freezing is generally not recommended. The freeze-thaw process can cause peptide aggregation and degradation, reducing biological activity and potentially increasing the risk of particulate matter in the solution.

Reconstituted peptides should be stored refrigerated (2–8°C) and used within 4–6 weeks.

Most peptide researchers use U100 insulin syringes (100 units = 1mL). The unit markings correspond to microlitre (µL) volumes:

• 10 units = 0.1 mL = 100 µL
• 20 units = 0.2 mL = 200 µL
• 50 units = 0.5 mL = 500 µL

Use our Dosage Calculator to determine exactly how many units to draw based on your vial concentration and desired dose in mcg.

Many research peptide doses are expressed per kilogram of bodyweight (mcg/kg). This means the dose scales with the individual's body mass. For example, if a protocol specifies 300 mcg/kg for an 80 kg individual: 300 × 80 = 24,000 mcg per dose.

Our Dosage Calculator handles this automatically — enter your weight, desired mcg/kg dose, and vial concentration to get the exact injection volume.

Peptide cycling refers to planned on/off periods of peptide administration. Cycling is used for several reasons:

• Receptor downregulation: Some peptides (especially GHRPs) can cause receptor desensitisation with continuous use, reducing efficacy over time
• Natural rhythm preservation: GH secretagogues work best when used to enhance natural pulsatile GH patterns, not suppress them
• Safety: Reducing cumulative exposure to any research compound is a standard precautionary approach

Common cycling patterns include 5 days on / 2 days off, or 8 weeks on / 4 weeks off, depending on the specific compound and protocol.

Properly stored lyophilised (powder) peptides typically have a shelf life of:

• Freezer (–20°C): 12–24 months (sometimes longer for very stable peptides)
• Refrigerator (2–8°C): 3–6 months
• Room temperature: Weeks to a few months (not recommended for long-term storage)

Always keep powder peptides sealed, away from moisture, light, and heat until ready to use.

Brief exposure to room temperature (during shipping or short-term handling) is generally acceptable for lyophilised peptides. The lyophilisation process creates a stable, dry form.

However, prolonged heat exposure can cause peptide degradation. If a lyophilised vial was exposed to elevated temperatures (above 25°C) for extended periods, the peptide may have partially degraded and potency may be reduced.

For reconstituted solutions, room temperature should be avoided entirely — always refrigerate and use within the recommended timeframe.

The safety profile of any research compound depends on the specific peptide, dose, administration route, individual health status, and duration of use. Many widely studied peptides (like BPC-157, Ipamorelin, GHK-Cu) have demonstrated favourable safety profiles in research, but the absence of large-scale human clinical trials means comprehensive safety data is limited for most.

Key considerations:

• Source quality matters enormously — pharmaceutical-grade compounded peptides from regulated pharmacies are very different from unverified RUO compounds
• Individual contraindications (see our Safety Guidelines) should always be reviewed
• Healthcare professional oversight is strongly recommended for any peptide protocol

Common side effects vary by peptide class but generally include:

• GLP-1 agonists (Semaglutide, Tirzepatide): Nausea, vomiting, constipation, injection site reactions
• GH Secretagogues (Ipamorelin, GHRP-2): Water retention, tingling, temporary fatigue, increased hunger (GHRP-6)
• Recovery peptides (BPC-157, TB-500): Generally well-tolerated; mild injection site reactions most common
• Cognitive peptides (Semax, Selank): Generally mild; possible initial fatigue or slight irritability

See our Safety Guidelines for a comprehensive adverse event recognition guide.

Many peptides are commonly combined in research protocols (called "stacking"). Well-documented combinations include CJC-1295 + Ipamorelin, BPC-157 + TB-500, and Semax + Selank. These stacks leverage complementary mechanisms for potentially synergistic outcomes.

However, potential interactions between peptides and other medications or supplements should always be considered. Our Interaction Checker tool (coming soon) will help evaluate these combinations. Until then, always consult a healthcare professional before combining research compounds.